Predictive. Prognostic. Personalized.
Vesta is Valar Labs’ genitourinary-focused portfolio of AI-powered pathology tests, designed to help physicians and patients make personalized, evidence-based decisions about cancer treatments.
The future of GU oncology is precision treatment. Lead the way with confidence.
Vesta Technology
Valar Labs’ research team has developed and validated multiple unique Vesta biomarker models in over 1,000 patients with Non-Muscle Invasive Bladder Cancer (NMIBC) using histology features.
Valar Labs’ board-certified pathologists created 500,000+ annotations of tumors and their microenvironment to train our Computational Histology Artificial Intelligence (CHAI) platform, grounding the technology in biology.
Leveraging existing tumor specimens, first-of-its-kind AI analyzes pathology slides and returns actionable results in days for timely treatment decisions.
By unlocking key features of the tumor and its microenvironment, BCGPredict identifies patients at a higher risk of not responding to BCG.1,2
Understand what’s best for each individual by adding personalized data to your clinical management strategy.3
Biomarker-present patients have a 2x elevated risk of non-response to BCG compared to biomarker-absent patients.
Patients who test biomarker-present demonstrated a higher likelihood of success with an alternative therapy.
Whatever your clinical care strategy, deeper insights based on tumor biology enable a more personalized plan.
Prognostic models stratify risks of high-grade recurrence and muscle-invasive progression better than existing guideline frameworks.1,4
Individual patient risk scores and projected actual risks over time can aid in patient counseling for surveillance, monitoring, and surgical management decisions.
Patients with high recurrence scores have a 2x elevated risk of high-grade recurrence over up to 24 months.
Patients with a high progression score have an almost 4x elevated risk of disease progression within 3 years.
Are you a:
Check out this informational brochure to better understand how Vesta can give you and your doctor a more personalized view of your cancer.
Download our one pager here.
Ready to incorporate Vesta into your practice?
Frequently asked questions about Vesta
What is Vesta?
Vesta is Valar Labs' GU-focused portfolio of AI-powered diagnostic tests, providing deep insights into each patient's unique disease using routine histology. Vesta tests are currently available in bladder cancer, with other indications in development.
Who is Vesta intended for?
Vesta Bladder tests are intended for patients with non-muscle invasive bladder cancer. Vesta Bladder Risk Stratify provides individualized risks of disease recurrence and progression, and Vesta Bladder BCGPredict is the only bladder cancer diagnostic that predicts treatment response to BCG, through histology alone.
How much does Vesta testing cost?
Valar Labs is committed to providing patient access regardless of finances. Our Financial Access Program supports patients with financial needs.
What is the turnaround time for the test?
You can expect Vesta Bladder test results back within approximately 3 days after the sample has arrived at our laboratory.
How can I order Vesta testing?
Vesta Bladder testing is offered through licensed physicians who treat patients with bladder cancer. Vesta tests are performed in Valar Labs' CLIA-certified laboratory.
Do I need an additional sample to run Vesta?
No, Vesta Bladder testing uses an existing sample from routine procedures already performed to diagnose bladder cancer. No additional procedure or sample collection is needed.
When is Vesta ordered in my diagnostic process?
Vesta Bladder testing can be ordered after a bladder cancer diagnosis is made to help clinical management planning.
Latest News
Ready for Vesta?
1. Lotan Y, Krishna V, Abuzeid WM, et al. Predicting Response to Intravesical Bacillus Calmette-Guérin in High-Risk Nonmuscle-Invasive Bladder Cancer Using an Artificial Intelligence–Powered Pathology Assay: Development and Validation in an International 12-Center Cohort. J Urol. 2025;213(2):192-204. 2. Lotan Y, Li R, Chang SS. AI Biomarkers Predict Poor Efficacy of BCG Rechallenge in Previously BCG-Treated Non-muscle Invasive Bladder Cancer. J Urol. Published online April 16, 2025. doi:10.1097/JU.0000000000004541 3. Packiam VT, McElree IM, Ghodoussipour S, et al. Presence of an Artificial Intelligence-powered Predictive Biomarker Is Associated with a Poor Response to Intravesical Bacillus Calmette-Guerin but Not to Intravesical Sequential Gemcitabine/Docetaxel in Patients with High-grade Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. Published online April 25, 2025. doi:10.1016/j.euo.2025.04.006 4. Chang SS, Launer B, Narayan V, et al. Computational Histology Artificial Intelligence (CHAI) Enhances Risk Stratification of High-grade Ta Non-muscle-invasive Bladder Cancer in a Multicenter Cohort: Comparison to Current European Association of Urology and American Urological Association Stratification Schemes. Eur Urol. Published online June 12, 2025. doi:10.1016/j.eururo.2025.05.035